Many patients with early stage
lung cancer treated with surgery relapse elsewhere in the body (metastatic
disease) and the the question arises as to whether they would benefit from
postOp chemotherapy (adjuvant chemotherapy) to prevent relapses. This works
well in breast cancer but the benefits in non-small cell lung cancer have
been small in earlier studies. By 2005
the NCCN guidelines recommend adjuvant chemotherapy in virtually all
cases but early stage I (see flow chart
here.)
To calculate survival benefits from adjuvant chemotherapy after resected
lung cancer go here
and see the most recent guidelines
here |
Trial | Patients | Chemo |
Survival Surgery Alone |
Survival Surgery + Chemo |
NCI-C | Stage I/II | Navelbine/Platinol X4 | 54%/5y | 69%/5y |
CALGB | Stage IB | Carbo/Taxol X4 | 51%/4y | 71%/4y |
Adjuvant chemotherapy in non-small cell lung cancer. Le Chevalier T. Semin Oncol. 1998 Aug;25(4 Suppl 9):62-5. Surgery is the main curative treatment of patients with non-small cell lung cancer (NSCLC), but half of all patients will experience local or distant failure after complete resection. An individual data-based meta-analysis has suggested a 13% reduction in the risk of death and an absolute benefit of 5% at 5 years with adjuvant cisplatin-containing chemotherapy in patients with resected NSCLC. These data led several national and international groups to initiate a new generation of adjuvant trials in resected NSCLC, and more than 2,500 patients have already been included in these randomized studies. Chemotherapy can also be proposed preoperatively. Two randomized studies, which included 60 patients each, strongly suggested a benefit from neoadjuvant chemotherapy in patients with stage III NSCLC. |
Vinorelbine plus Cisplatin vs.
Observation in Resected Non–Small-Cell Lung Cancer
Timothy Winton, M.D., for the National
Cancer Institute of Canada Clinical Trials Group and the National Cancer
Institute of the United States Intergroup JBR.10 Trial Investigators.
NEJM 2005;352:2589-2597
|
We undertook to determine
whether adjuvant vinorelbine plus cisplatin prolongs overall
survival among patients with completely resected early-stage
non–small-cell lung cancer. We randomly assigned patients with
completely resected stage IB or stage II non–small-cell lung
cancer to vinorelbine plus cisplatin or to observation. The
primary end point was overall survival; principal secondary end
points were recurrence-free survival and the toxicity and
safety of the regimen.
Results A total of 482 patients underwent randomization to vinorelbine plus cisplatin (242 patients) or observation (240); 45 percent of the patients had pathological stage IB disease and 55 percent had stage II, and all had an Eastern Cooperative Oncology Group performance status score of 0 or 1. In both groups, the median age was 61 years, 65 percent were men, and 53 percent had adenocarcinomas. Chemotherapy caused neutropenia in 88 percent of patients (including grade 3 febrile neutropenia in 7 percent) and death from toxic effects in two patients (0.8 percent). Nonhematologic toxic effects of chemotherapy were fatigue (81 percent of patients), nausea (80 percent), anorexia (55 percent), vomiting (48 percent), neuropathy (48 percent), and constipation (47 percent), but severe (grade 3 or greater) toxic effects were uncommon (<10 percent). Overall survival was significantly prolonged in the chemotherapy group as compared with the observation group (94 vs. 73 months; hazard ratio for death, 0.69; P=0.04), as was relapse-free survival (not reached vs. 46.7 months; hazard ratio for recurrence, 0.60; P<0.001). Five-year survival rates were 69 percent and 54 percent, respectively (P=0.03). Conclusions Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non–small-cell lung cancer. Subgroup analyses indicate that the survival advantage in our trial was most prominent in patients with stage II disease. We cannot explain why the benefit in patients with stage IB disease was less and did not reach statistical significance (7 percent benefit at five years, vs. 20 percent among those with stage II disease). The number of patients with stage IB disease was small, the number of events was smaller than had been anticipated when the subgroup analysis was planned, and the statistical test for stage-by-treatment interaction was not significant (P=0.13). Therefore, it is important not to place too much emphasis on this subgroup analysis. A British Medical Research Council meta-analysis of cisplatin-based
chemotherapy after surgery for stage I through stage III
non–small-cell lung cancer showed a
13 percent reduction in the risk
of death and an
absolute improvement in survival of 5 percent at five
years, but
when compared with observation alone after surgery, the
difference was statistically insignificant (P=0.08). More
recently, a large international trial of adjuvant chemotherapy
that used cisplatin plus either a vinca alkaloid or etoposide
(International Adjuvant Lung Cancer Trial [IALT]) reported similar
results, with a 4.1 percent
improvement in five-year survival
(hazard ratio, 0.86; P<0.03) The median survival after chemotherapy was significantly prolonged, at 94 months (95 percent confidence interval, 73 to not reached), as compared with 73 months (95 percent confidence interval, 48 to not reached) in the observation group (hazard ratio, 0.69; 95 percent confidence interval, 0.52 to 0.91; P=0.009; P=0.04 after adjustment for interim analyses). There was an absolute survival advantage of 15 percentage points at five years — 69 percent (95 percent confidence interval, 62 to 75 percent) in the vinorelbine–cisplatin group and 54 percent (95 percent confidence interval, 48 to 61 percent) with observation alone (P=0.03). Subgroup analyses according to stratification factors did not show a statistically significant improvement in overall survival among patients with stage IB non–small-cell lung cancer in the chemotherapy group as compared with the observation group (P=0.79) The median survival among patients with stage II non–small-cell lung cancer was 41 months in the observation group and 80 months in the chemotherapy group (hazard ratio, 0.59; 95 percent confidence interval, 0.42 to 0.85; P=0.004). |